Taking a Closer Look At Halozyme Therapeutics Inc (HALO) Following Its Recent Trade

Daniel Torres

In a filing, Halozyme Therapeutics Inc revealed its SVP, CHIEF OPERATING OFFICER Caudill Cortney unloaded Company’s shares for reported $0.28 million on Nov 01 ’25. In the deal valued at $65.19 per share,4,263 shares were sold. As a result of this transaction, Caudill Cortney now holds 12,737 shares worth roughly $0.86 million.

Then, Connaughton Bernadette sold 829 shares, generating $59,356 in total proceeds. Upon selling the shares at $71.60, the Director now owns 42,123 shares.

Before that, Torley Helen sold 16,569 shares. Halozyme Therapeutics Inc shares valued at $1,141,925 were divested by the PRESIDENT AND CEO at a price of $68.92 per share. As a result of the transaction, Torley Helen now holds 708,719 shares, worth roughly $47.73 million.

Goldman downgraded its Halozyme Therapeutics Inc [HALO] rating to a Sell from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who increased its forecast for the stock in mid October from “an Underperform” to “a Market perform”. Morgan Stanley also remained covering HALO and has increased its forecast on August 06, 2025 with a “an Overweight” recommendation from previously “an Equal-weight” rating.

Price Performance Review of HALO

On Friday, Halozyme Therapeutics Inc [NASDAQ:HALO] saw its stock jump 3.44% to $67.35. Over the last five days, the stock has gained 8.26%. Halozyme Therapeutics Inc shares have risen nearly 38.58% since the year began. Nevertheless, the stocks have risen 40.87% over the past one year. While a 52-week high of $79.50 was reached on 09/23/25, a 52-week low of $46.26 was recorded on 05/14/25.

Levels Of Support And Resistance For HALO Stock

The 24-hour chart illustrates a support level at 65.80, which if violated will result in even more drops to 64.24. On the upside, there is a resistance level at 68.22. A further resistance level may holdings at 69.08.

How much short interest is there in Halozyme Therapeutics Inc?

A steep rise in short interest was recorded in Halozyme Therapeutics Inc stocks on 2025-11-28, growing by 1.07 million shares to a total of 12.37 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 11.31 million shares. There was a rise of 8.63%, which implies that there is a positive sentiment for the stock.

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.